Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

PRECiSE 1 Results

Significant improvements in clinical response vs placebo at Week 6 (35% vs 27%, P=.02) and Week 26 (37% vs 27%, P≤.05)

At Week 6, significantly more patients in the CIMZIA group had responded to treatment versus patients in the placebo group (35% vs 27%).1,2

This statistically significant difference in response rates was also seen at Week 26 (37% of the CIMZIA group vs 27% of the placebo group), support that CIMZIA provides patients with maintained clinical response.2

Clinical response* at Week 6 and Weeks 6 and 26 was seen regardless of concomitant corticosteroid or immunosuppressant therapy or prior infliximab use.1

*Clinical response was defined as a decrease in Crohn's Disease Activity Index score of ≥100 points.

Serious and sometimes fatal side effects have been reported with CIMZIA. These include tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

References:

  1. Sandborn WJ, Feagan BG, Stoinov S, et al; for the PRECiSE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;375:228-238.
  2. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA